ResearcherThe University of TokyoActive in the last 2 years
Gen Kimura
Matched on ORCID iD 0000-0003-2652-1798; OpenAlex author ID A5072969214. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 4
- Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117071↗
- Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment. Co-author DOI 10.1038/s41598-025-32222-4↗
- Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… Co-author DOI 10.1007/s00280-020-04110-3↗
- Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Makoto Sano · 3 shared papers, 2020–2026 · strength 0.60
- Paper Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages i… DOI 10.1038/s41598-025-32222-4↗
- Paper Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. DOI 10.1016/j.isci.2026.117071↗
- Paper Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancrea… DOI 10.1038/s41598-020-78320-3↗
- Koji Miyabayashi · 3 shared papers, 2020–2026 · strength 0.60
- Paper Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages i… DOI 10.1038/s41598-025-32222-4↗
- Paper Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. DOI 10.1016/j.isci.2026.117071↗
- Paper Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancrea… DOI 10.1038/s41598-020-78320-3↗
- Hideaki Ijichi · 3 shared papers, 2020–2026 · strength 0.60
- Paper Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages i… DOI 10.1038/s41598-025-32222-4↗
- Paper Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. DOI 10.1016/j.isci.2026.117071↗
- Paper Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancrea… DOI 10.1038/s41598-020-78320-3↗
- Mitsuhiro Fujishiro · 2 shared papers, 2025–2026 · strength 0.51
- Takahiro Kishikawa · 1 shared paper, 2025 · strength 0.27
- Genso Notoya · 1 shared paper, 2025 · strength 0.27
- Akiyoshi Hirayama · 1 shared paper, 2026 · strength 0.24
- Yohei Masugi · 1 shared paper, 2026 · strength 0.24
- Yoshimi Ichimaru · 1 shared paper, 2026 · strength 0.24
- Atsushi Masamune · 1 shared paper, 2026 · strength 0.24
- Toru Otsuru · 1 shared paper, 2020 · strength 0.09
- Motoyasu Kan · 1 shared paper, 2020 · strength 0.09
- Kumiko Umemoto · 1 shared paper, 2020 · strength 0.09
- Shuichi Mitsunaga · 1 shared paper, 2020 · strength 0.09
- Mitsuhito Sasaki · 1 shared paper, 2020 · strength 0.09
- Masafumi Ikeda · 1 shared paper, 2020 · strength 0.09
- Hiroshi Imaoka · 1 shared paper, 2020 · strength 0.09
- Dai Mohri · 1 shared paper, 2020 · strength 0.09
- Ryota Takahashi · 1 shared paper, 2020 · strength 0.09
- Hiroyuki Isayama · 1 shared paper, 2020 · strength 0.09
- Keisuke Yamamoto · 1 shared paper, 2020 · strength 0.09
- Kazuhiko Koike · 1 shared paper, 2020 · strength 0.09
- Harold L. Moses · 1 shared paper, 2020 · strength 0.09
- Yousuke Nakai · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.